- Details
- Adam Kibel and Mary-Ellen Taplin join Alicia Morgans in a conversation about optimizing the care of men with localized prostate cancer, both systemic therapy, and surgical techniques and a combination of the two. They discuss the treatment landscape and their insights into what the field could consider for patients with localized disease. Biographies: Adam Kibel, MD, Chief, Division of Urology Ell...
|
- Details
- Charles Ryan is joined by Fernando Maluf, leader of genitourinary oncology in Brazil, who shares details on the upcoming Latin American Oncology Group (LACOG), a cooperative group consensus meeting. This cooperative group, developed a consensus to strive for answers on screening for late stage of prostate cancer, from the experts from all over the world particularly for developing countries in Afr...
|
- Details
- Michael Morris, MD, and Larry (Lawrence) Schwartz joins Charles Ryan, MD in a conversation about credentialing imaging as an outcome measure in prostate cancer and its impact in clinical trials. They focus on the following questions: How do we credential images? How do we perform them? And how do we interpret them? Their conversation also focuses on determining progression-free survival (PFS) from...
|
- Details
- Paul Nguyen and Alicia Morgans discuss a number of hot topics in radiation oncology for prostate cancer, highlighting topics of radiating the primary in low-volume metastatic hormone-sensitive disease and the benefit in terms of disease control and prostate cancer-specific outcomes. Paul overviews the METACURE trial (NCT03436654) looking at either a high-risk or the oligometastatic population, and...
|
- Details
- Benjamin Maughan shares his perspectives on clinical practice-changing data for prostate cancer in this conversation with Petros Grivas. The conversation includes discussions of the data from the ARCHES and TITAN trials for treatment on nonmetastatic prostate cancer and how the combination hormone therapies may impact treatment decisions. New data was also discussed from ENZAMET where the addition...
|
- Details
- Alicia Morgans and Brenda Martone discuss the upcoming Advanced Prostate Cancer Consensus Conference (APCCC 2019). This global conference focuses on the grey areas where Level 1 Evidence is not available to guide treatment decisions in the clinic. Experts from around the globe will gather in Basel Switzerland from August 28 - August 31 to discuss areas of controversy in the treatment of prostate c...
|
- Details
- Silke Gillessen, MD and Aurelius Omlin, MD discuss the inception of the biennial Advanced Prostate Cancer Consensus Conference (APCCC) which will be held in Basel this August. The intent of the meeting is to drive international consensus on key areas of prostate cancer practice where there are no clear guidelines or level 1 evidence. 75% of the panelists must agree on each topic to reach a consens...
|
- Details
- Daniel Spratt and Todd Morgan discuss the analysis of why is it that black men appear to be dying more often of prostate cancer. They review their approach to understanding more about this real-world question. Biographies: Todd Matthew Morgan MD Associate Professor Specialties: Urology Area of Practice: Prostate Cancer, including robotic prostatectomy and active surveillance; Bladder Cancer, inclu...
|
- Details
- Alicia Morgans invites Claire Pernar to highlight her efforts on the topic of cognitive function in men with prostate cancer. Cognitive impairment is a key component of wellbeing in men with prostate cancer, and it can affect men's thinking, their language, and their memory. This is an area many seek to understand and to identify any unmet needs. Claire's work is being facilitated in the context o...
|
- Details
- Oliver Sartor, MD discusses his contributions to the recent publication in JAMA Oncology on the prevalence of germline variants in prostate cancer and the implications for genetic testing guidelines. 3600 patients had various forms of germiline genetic testing performed and were available for this analysis. In the dataset, 17% of patients had germline variants and 30% of those were BRCA1/BRCA2. In...
|
